161 related articles for article (PubMed ID: 36681824)
1. Prognostic role of pretreatment
Yang T; Liu S; Zuo R; Liang H; Xu L; Wang Z; Chen X; Pang H
BMC Med Imaging; 2023 Jan; 23(1):12. PubMed ID: 36681824
[TBL] [Abstract][Full Text] [Related]
2. Nomograms based on SUVmax of
Li H; Shao G; Zhang Y; Chen X; Du C; Wang K; Gao Z
Cancer Imaging; 2021 Jan; 21(1):9. PubMed ID: 33419476
[TBL] [Abstract][Full Text] [Related]
3. Texture analysis of 18F-FDG PET/CT and CECT: Prediction of refractoriness of Hodgkin lymphoma with mediastinal bulk involvement.
Abenavoli EM; Linguanti F; Anichini M; Miele V; Mungai F; Palazzo M; Nassi L; Puccini B; Romano I; Sordi B; Sciagrà R; Simontacchi G; Vannucchi AM; Berti V
Hematol Oncol; 2024 Mar; 42(2):e3261. PubMed ID: 38454623
[TBL] [Abstract][Full Text] [Related]
4. Usefulness of
Xian WJ; Feng YL; Wang Y; Yang M; Lu SN
Br J Radiol; 2022 Jan; 95(1129):20210279. PubMed ID: 34813375
[TBL] [Abstract][Full Text] [Related]
5. Early
Chen A; Mokrane FZ; Schwartz LH; Morschhauser F; Stamatoullas A; Schiano de Colella JM; Vercellino L; Casasnovas O; Chauchet A; Delmer A; Nicolas-Virelizier E; Ghesquières H; Moles-Moreau MP; Schmitt A; Dulery R; Bouabdallah K; Borel C; Touati M; Deau-Fischer B; Peyrade F; Seban RD; Manson G; Armand P; Houot R; Dercle L
J Nucl Med; 2020 May; 61(5):649-654. PubMed ID: 31628220
[TBL] [Abstract][Full Text] [Related]
6. The value of FDG PET/CT imaging in outcome prediction and response assessment of lymphoma patients treated with immunotherapy: a meta-analysis and systematic review.
Kiamanesh Z; Ayati N; Sadeghi R; Hawkes E; Lee ST; Scott AM
Eur J Nucl Med Mol Imaging; 2022 Nov; 49(13):4661-4676. PubMed ID: 35932329
[TBL] [Abstract][Full Text] [Related]
7. Intratumor Heterogeneity Assessed by
Lue KH; Wu YF; Liu SH; Hsieh TC; Chuang KS; Lin HH; Chen YH
Acad Radiol; 2020 Aug; 27(8):e183-e192. PubMed ID: 31761665
[TBL] [Abstract][Full Text] [Related]
8. [Prognostic evaluation value of (18)F-FDG PET-CT in Hodgkin's lymphoma after treatment].
Wan H; Liu P; Liang Y; Jiang SY; Lyu L; Zhang ZW; Wu N; Liu Y
Zhonghua Zhong Liu Za Zhi; 2021 Dec; 43(12):1275-1281. PubMed ID: 34915636
[No Abstract] [Full Text] [Related]
9. Combined prognostic role of TARC and interim
Husi K; Pinczés LI; Fejes Z; Nagy B; Illés Á; Miltényi Z
Hell J Nucl Med; 2022; 25(2):125-131. PubMed ID: 35913858
[TBL] [Abstract][Full Text] [Related]
10. Prognostic role of baseline 18F-FDG PET/CT metabolic parameters in elderly HL: a two-center experience in 123 patients.
Albano D; Mazzoletti A; Spallino M; Muzi C; Zilioli VR; Pagani C; Tucci A; Rossetti C; Giubbini R; Bertagna F
Ann Hematol; 2020 Jun; 99(6):1321-1330. PubMed ID: 32333153
[TBL] [Abstract][Full Text] [Related]
11. Pediatric Hodgkin Lymphoma: Predictive value of interim 18F-FDG PET/CT in therapy response assessment.
Ferrari C; Niccoli Asabella A; Merenda N; Altini C; Fanelli M; Muggeo P; De Leonardis F; Perillo T; Santoro N; Rubini G
Medicine (Baltimore); 2017 Feb; 96(5):e5973. PubMed ID: 28151888
[TBL] [Abstract][Full Text] [Related]
12. [Prognostic value of pretreatment (18)F-FDG PET-CT metabolic parameters in patients with advanced extranodal NK/T cell lymphoma].
Wu LL; Liang JH; Wang L; Xu W; Ding CY
Zhonghua Zhong Liu Za Zhi; 2019 Nov; 41(11):831-836. PubMed ID: 31770850
[No Abstract] [Full Text] [Related]
13. Construction and validation of an
Dong X; Wang R; Ying X; Xu J; Yan J; Xu P; Peng Y; Chen B
Hematology; 2024 Dec; 29(1):2329029. PubMed ID: 38488443
[TBL] [Abstract][Full Text] [Related]
14. Prognostic 18F-FDG PET biomarkers in metastatic mucosal and cutaneous melanoma treated with immune checkpoint inhibitors targeting PD-1 and CTLA-4.
Seban RD; Moya-Plana A; Antonios L; Yeh R; Marabelle A; Deutsch E; Schwartz LH; Gómez RGH; Saenger Y; Robert C; Ammari S; Dercle L
Eur J Nucl Med Mol Imaging; 2020 Sep; 47(10):2301-2312. PubMed ID: 32206839
[TBL] [Abstract][Full Text] [Related]
15. Tumor metabolic and secondary lymphoid organ metabolic markers on 18F-fludeoxyglucose positron emission tomography predict prognosis of immune checkpoint inhibitors in advanced lung cancer.
Jin P; Bai M; Liu J; Yu J; Meng X
Front Immunol; 2022; 13():1004351. PubMed ID: 36341372
[TBL] [Abstract][Full Text] [Related]
16.
Eisazadeh R; Mirshahvalad SA
Clin Imaging; 2022 Dec; 92():25-31. PubMed ID: 36179394
[TBL] [Abstract][Full Text] [Related]
17. Post-transplantation Fluorine-18 Fluorodeoxyglucose Positron Emission Tomography in Patients with Lymphoblastic Lymphoma is an Independent Prognostic Factor with an Impact on Progression-Free Survival but not Overall Survival.
Dai N; Liu H; Deng S; Sang S; Wu Y
Technol Cancer Res Treat; 2021; 20():15330338211056478. PubMed ID: 34806464
[No Abstract] [Full Text] [Related]
18. Comparison of clinical and PET-derived prognostic factors in patients with non-Hodgkin lymphoma: a special emphasis on bone marrow involvement.
Kupik O; Akin S; Tuncel M; Eren G; Türker A; Kars A; Erbaş B
Nucl Med Commun; 2020 Jun; 41(6):540-549. PubMed ID: 32209829
[TBL] [Abstract][Full Text] [Related]
19. Prognostic value of metabolic tumour volume on baseline
Shagera QA; Cheon GJ; Koh Y; Yoo MY; Kang KW; Lee DS; Kim EE; Yoon SS; Chung JK
Eur J Nucl Med Mol Imaging; 2019 Jul; 46(7):1417-1427. PubMed ID: 30941463
[TBL] [Abstract][Full Text] [Related]
20. 18-Fluorodeoxyglucose positron emission tomography/computed tomography for assessment of response to brentuximab vedotin treatment in relapsed and refractory Hodgkin lymphoma.
Kahraman D; Theurich S; Rothe A; Kuhnert G; Sasse S; Scheid C; Dietlein M; Drzezga A; von Bergwelt-Baildon M; Kobe C
Leuk Lymphoma; 2014 Apr; 55(4):811-6. PubMed ID: 23805904
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
